Alpha- Antitrypsin Deficiency - Market Insight, Epidemiology and Market Forecast - 2027

  • ID: 4085564
  • Drug Pipelines
  • 127 pages
  • DelveInsight
1 of 3
The ‘Alpha- Antitrypsin Deficiency (AATD) - Market Insights, Epidemiology and Market Forecast-2027’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of AATD from 2016 to 2027 segmented by the US, EU-5 countries and Rest of the World (RoW). The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan
Study Period: 2016-2027

Alpha- Antitrypsin Deficiency (AATD) - Disease Understanding and Treatment Algorithm

The Alpha- Antitrypsin Deficiency (AATD) market report gives the thorough understanding of the AATD by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for AATD in the US, Europe, and Japan.

Alpha- Antitrypsin Deficiency (AATD) Epidemiology

The AATD epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented into two parts: Population at the risk of developing AATD on the basis of allele [PiSS, PiSZ, PiZZ) and Prevalent cases of AATD in 6 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom)]. As AATD is quite rare in Japan, the report features the diagnosed population of AATD in Japan.

According to the report, the prevalent cases of AATD was 185,860 in 2016 in 6MM and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. Among 6MM, United States account for highest prevalent cases of AATD with 113,808 prevalent cases in 2016 followed by Germany.

Alpha- Antitrypsin Deficiency (AATD) Drug Chapters

This segment of the AATD report encloses the detailed analysis of marketed drugs and late stage (Phase-III) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

AATD is rare disease which is highly under diagnosed and treated by the augmentation therapy products. United States Food and Drug Administration (FDA) has approved four augmentation therapies till date Prolastin-C (Grifols), Aralast NP (Shire), Zemaira (CSL Behring) and Glassia (Kamada Ltd.) and more potential therapies are on the horizon. This report includes detailed chapters of marketed products along with the promising upcoming therapies.

Alpha- Antitrypsin Deficiency (AATD) Market Outlook

The AATD market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The report provides global market share of AATD i.e., 6 Major Markets [United States and EU5 (Germany, Spain, Italy, France and United Kingdom)] and Rest of World (RoW). In 2016, global market size of AATD was USD 918.78 million and, is expected to grow during the forecast period of 2018-2027.

The region-wise market size for MS in US, EU-5 countries (Germany, France, Italy, Spain and the U.K.) and Rest of the World (RoW) shows highest market size in US, followed by Germany, the lowest being in the UK due to the difference of opinion between regulatory authorities and the manufacturer companies owing to the reimbursement policies.

Alpha- Antitrypsin Deficiency (AATD) Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Alpha- Antitrypsin Deficiency (AATD) Report Insights
  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies
Alpha- Antitrypsin Deficiency (AATD) Report Key Strengths
  • 10 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition
Alpha- Antitrypsin Deficiency (AATD) Report Assessment
  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
Key Benefits
  • This report will help to develop Business Strategies by understanding the trends shaping and driving the AATD market
  • Organize sales and marketing efforts by identifying the best opportunities for AATD market
  • To understand the future market competition in the AATD market.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Report Introduction

2. Alpha Antitrypsin Deficiency Market Overview at a Glance
2.1. Market Share Distribution of Alpha Antitrypsin Deficiency in 2016
2.2. Market Share Distribution of Alpha Antitrypsin Deficiency in 2027

3. Disease Background and Overview: Alpha Antitrypsin Deficiency
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Genetic Inheritance of Alpha Antitrypsin Deficiency
3.6. Pathophysiology
3.7. Complications
3.8. Diagnosis
3.9. Treatment
3.10. Diagnostic Delay

4. Epidemiology and Patient Population
4.1. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM
4.2. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 7MM – By Region
4.3. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM – Distribution (2016)
4.4. Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6MM – Distribution (2027)
4.5. Epidemiology of Alpha-1-Antitrypsin Deficiency- By Country
4.5.1. United States
4.5.1.1. Assumptions and Rationale
4.5.1.2. Population at risk of Alpha Antitrypsin Deficiency in United States
4.5.1.3. Prevalent Population of Alpha Antitrypsin Deficiency
4.5.2. EU5
4.5.2.1. Assumptions and Rationale
4.5.2.2. Germany
4.5.2.2.1. Population at risk of Alpha Antitrypsin Deficiency in Germany
4.5.2.2.2. Prevalent Population of Alpha Antitrypsin Deficiency in Germany
4.5.2.3. France
4.5.2.3.1. Population at risk of Alpha Antitrypsin Deficiency in France
4.5.2.3.2. Prevalent Population of Alpha Antitrypsin Deficiency in France
4.5.2.4. Italy
4.5.2.4.1. Population at risk of Alpha Antitrypsin Deficiency in Italy
4.5.2.4.2. Prevalent Population of Alpha Antitrypsin Deficiency in Italy
4.5.2.5. Spain
4.5.2.5.1. Population at risk of Alpha Antitrypsin Deficiency in Spain
4.5.2.5.2. Prevalent Population of Alpha Antitrypsin Deficiency in Spain
4.5.2.6. United Kingdom
4.5.2.6.1. Population at risk of Alpha Antitrypsin Deficiency in UK
4.5.2.6.2. Prevalent Population of Alpha Antitrypsin Deficiency in UK
4.5.3. Japan
4.5.3.1. Diagnosed Population of Alpha Antitrypsin Deficiency in Japan

5. Treatment Algorithm
5.1. Management of Alpha-Antitrypsin (AAT) Deficiency with Lung Disease
5.2. Management of Alpha-Antitrypsin (AAT) Deficiency with Liver Disease

6. Unmet Needs

7. Marketed Drugs
7.1. Prolastin C: Grifols
7.1.1. Drug Description
7.1.2. Mechanism of Action
7.1.3. Regulatory Milestones
7.1.4. Advantages & Disadvantages
7.1.5. Product Profile
7.1.6. Safety and Efficacy of Prolastin-C
7.2. Glassia: Kamada
7.2.1. Drug Description
7.2.2. Mechanism of Action
7.2.3. Regulatory Milestones
7.2.4. Advantages & Disadvantages
7.2.5. Safety and Efficacy of Glassia
7.2.6. Product Profile
7.3. Aralast: Shire
7.3.1. Drug Description
7.3.2. Mechanism of Action
7.3.3. Regulatory Milestones
7.3.4. Advantages & Disadvantages
7.3.5. Safety and Efficacy of Aralast
7.3.6. Product Profile
7.4. Zemaira: CSL Behring
7.4.1. Drug Description
7.4.2. Mechanism of Action
7.4.3. Regulatory Milestones
7.4.4. Advantages & Disadvantages
7.4.5. Safety and Efficacy of Zemaira
7.4.6. Product Profile
7.5. Alfalastin: LFB Biotechnologies
7.5.1. Description
7.5.2. Regulatory Milestones
7.5.3. Advantages and Disadvantages
7.5.4. Product Profile
7.5.5. Safety and Efficacy
7.5.6. Side effects
7.6. Trypsone: Grifols
7.7. Description
7.8. Regulatory Milestones
7.9. Advantages and Disadvantages
7.10. Product Profile
7.11. Efficacy and Safety
7.12. Side effects

8. Emerging Therapies
8.1. Inhaled AAT (Glassia IH): Kamada Ltd.
8.2. Regulatory Milestones
8.3. Product Development Activities
8.4. Clinical Development
8.5. Product Profile

9. Alpha Antitrypsin Deficiency: Global Market Analysis
9.1. Global Market Size of AATD
9.2. Global Percentage Share of drugs marketed for AATD
9.3. Global Market Sales of AATD by Products
9.4. Global Treated Population for AATD

10. Alpha Antitrypsin Deficiency: Country-Wise Market Analysis
10.1. United States
10.1.1. Market Size of AATD in United States
10.1.2. Percentage Share of drugs marketed for AATD in United States
10.1.3. Market Sales of Alpha Antitrypsin Deficiency by Products in United States
10.1.4. Treated Population of AATD in United States
10.2. EU-5
10.2.1. Germany
10.2.1.1. Market Size of AATD in Germany
10.2.1.2. Percentage Share of drugs marketed for AATD in Germany
10.2.1.3. Market Sales of Alpha Antitrypsin Deficiency by Products in Germany
10.2.1.4. Treated Population of AATD in Germany
10.2.2. France
10.2.2.1. Market Size of AATD in France
10.2.2.2. Percentage Share of drugs marketed for AATD in France
10.2.2.3. Market Sales of Alpha Antitrypsin Deficiency by Products in France
10.2.2.4. Treated Population of AATD in France
10.2.3. Italy
10.2.3.1. Market Size of AATD in Italy
10.2.3.2. Percentage Share of drugs marketed for AATD in Italy
10.2.3.3. Market Sales of Alpha Antitrypsin Deficiency by Products in Italy
10.2.3.4. Treated Population of AATD in Italy
10.2.4. Spain
10.2.4.1. Market Size of AATD in Spain
10.2.4.2. Percentage Share of drugs marketed for AATD in Spain
10.2.4.3. Market Sales of Alpha Antitrypsin Deficiency by Products in Spain
10.2.4.4. Treated Population of AATD in Spain
10.2.5. United Kingdom
10.2.5.1. Market Size of AATD in United Kingdom
10.2.5.2. Percentage Share of drugs marketed for AATD in United Kingdom
10.2.5.3. Market Sales of Alpha Antitrypsin Deficiency by Products in UK
10.2.5.4. Treated Population of AATD in UK
10.3. Rest of the World (RoW)

11. Grifols Initiatives towards Alpha Anti-trypsin deficiency

12. USFDA Initiatives for patients with Alpha-1 Antitrypsin Deficiency (AATD)

13. Market Drivers

14. Market Barriers

15. Appendix

16. Report Methodology
16.1. Sources Used

17. Consulting Services

18. Disclaimer

19. About the Publisher

List of Tables:
Table 1: Total Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6 MM (2016-2027)
Table 2: Prevalent Population of Alpha-1-Antitrypsin Deficiency in 7MM (2016-2027)
Table 3: Population at risk of Alpha Antitrypsin Deficiency in United States (2016-2027)
Table 4: Prevalent Population of Alpha Antitrypsin Deficiency in United States (2016-2027)
Table 5: Population at risk of Alpha Antitrypsin Deficiency in Germany (2016-2027)
Table 6: Prevalent Population of Alpha Antitrypsin Deficiency in Germany (2016-2027)
Table 7: Population at risk of Alpha Antitrypsin Deficiency in France (2016-2027)
Table 8: Prevalent Population of Alpha Antitrypsin Deficiency in France (2016-2027)
Table 9: Population at risk of Alpha Antitrypsin Deficiency in Italy (2016-2027)
Table 10: Prevalent Population of Alpha Antitrypsin Deficiency in Italy (2016-2027)
Table 11: Population at risk of Alpha Antitrypsin Deficiency in Spain (2016-2027)
Table 12: Prevalent Population of Alpha Antitrypsin Deficiency in Spain (2016-2027)
Table 13: Population at risk of Alpha Antitrypsin Deficiency in United Kingdom (2016-2027)
Table 14: Prevalent Population of Alpha Antitrypsin Deficiency in United Kingdom (2016-2027)
Table 15: Diagnosed Population of Alpha Antitrypsin Deficiency in Japan (2016-2027)
Table 16: Global Market Size of Alpha Antitrypsin Deficiency in USD Million (2016-2027)
Table 17: Global Percentage share of Drugs marketed for AATD (2017)
Table 18: Global Percentage share of Drugs marketed for AATD (2027)
Table 19: Global Market Sales of Alpha Antitrypsin Deficiency by Products in USD, Million (2016-2027)
Table 20: Global Treated Population of Alpha Antitrypsin Deficiency (2016-2027)
Table 21: United States Market Size of Alpha Antitrypsin Deficiency in USD, Million (2016-2027)
Table 22: Percentage share of Drugs marketed for AATD in United States (2017)
Table 23: Percentage share of Drugs marketed for AATD in United States (2027)
Table 24: US Market Sales of Alpha Antitrypsin Deficiency by Products in USD, Million (2016-2027)
Table 25: Treated Population of Alpha Antitrypsin Deficiency in the United States (2016-2027)
Table 26: Germany Market Size of Alpha Antitrypsin Deficiency in USD, Million (2016-2027)
Table 27: Percentage share of Drugs marketed for AATD in Germany (2017)
Table 28: Percentage share of Drugs marketed for AATD in Germany (2027)
Table 29: Germany Market Sales of Alpha Antitrypsin Deficiency by Products in USD, Million (2016-2027)
Table 30: Treated Population of Alpha Antitrypsin Deficiency in the Germany (2016-2027)
Table 31: France Market Size of Alpha Antitrypsin Deficiency in USD, Million (2016-2027)
Table 32: Percentage share of Drugs marketed for AATD in France (2017)
Table 33: Percentage share of Drugs marketed for AATD in France (2027)
Table 34: France Market Sales of Alpha Antitrypsin Deficiency by Products in USD, Million (2016-2027)
Table 35: Treated Population of Alpha Antitrypsin Deficiency in France (2016-2027)
Table 36: Italy Market Size of Alpha Antitrypsin Deficiency in USD, Million (2016-2027)
Table 37: Percentage share of Drugs marketed for AATD in Italy (2017)
Table 38: Percentage share of Drugs marketed for AATD in Italy (2027)
Table 39: Italy Market Sales of Alpha Antitrypsin Deficiency by Products in USD, Million (2016-2027)
Table 40: Treated Population of Alpha Antitrypsin Deficiency in Italy (2016-2027)
Table 41: Spain Market Size of Alpha Antitrypsin Deficiency in USD, Million (2016-2027)
Table 42: Percentage share of Drugs marketed for AATD in Spain (2017)
Table 43: Percentage share of Drugs marketed for AATD in Spain (2027)
Table 44: Spain Market Sales of Alpha Antitrypsin Deficiency by Products in USD, Million (2016-2027)
Table 45: Treated Population of Alpha Antitrypsin Deficiency in Spain (2016-2027)
Table 46: United Kingdom Market Size of Alpha Antitrypsin Deficiency in USD, Million (2016-2027)
Table 47: Percentage share of Drugs marketed for AATD in UK (2018)
Table 48: Percentage share of Drugs marketed for AATD in UK (2027)
Table 49: UK Market Sales of Alpha Antitrypsin Deficiency by Products in USD, Million (2016-2027)
Table 50: Treated Population of Alpha Antitrypsin Deficiency in the United Kingdom (2016-2027)
Table 51:RoW Market Size of Alpha Antitrypsin Deficiency in USD, Million (2016-2027)

List of Figures:
Figure 1: Pathogenesis of Alpha Antitrypsin Deficiency
Figure 2: Diagnostic Algorithm of Alpha Antitrypsin Deficiency
Figure 3: General Treatment of Alpha Antitrypsin Deficiency
Figure 4: Total Prevalent Population of Alpha-1-Antitrypsin Deficiency in 6 MM (2016-2027)
Figure 5: Prevalent Population of Alpha-1-Antitrypsin Deficiency in 7MM (2016-2027)
Figure 6: Population at risk of Alpha Antitrypsin Deficiency in United States (2016-2027)
Figure 7: Prevalent Population of Alpha Antitrypsin Deficiency in United States (2016-2027)
Figure 8: Population at risk of Alpha Antitrypsin Deficiency in Germany (2016-2027)
Figure 9: Prevalent Population of Alpha Antitrypsin Deficiency in Germany (2016-2027)
Figure 10: Population at risk of Alpha Antitrypsin Deficiency in France (2016-2027)
Figure 11: Prevalent Population of Alpha Antitrypsin Deficiency in France (2016-2027)
Figure 12: Population at risk of Alpha Antitrypsin Deficiency in Italy (2016-2027)
Figure 13: Prevalent Population of Alpha Antitrypsin Deficiency in Italy (2016-2027)
Figure 14: Population at risk of Alpha Antitrypsin Deficiency in Spain ( (2016-2027)
Figure 15: Prevalent Population of Alpha Antitrypsin Deficiency in Spain (2016-2027)
Figure 16: Population at risk of Alpha Antitrypsin Deficiency in United Kingdom (2016-2027)
Figure 17: Prevalent Population of Alpha Antitrypsin Deficiency in United Kingdom (2016-2027)
Figure 18: Diagnosed Population of Alpha Antitrypsin Deficiency in Japan (2016-2027)
Figure 19: Global Market Size of Alpha Antitrypsin Deficiency in USD, Million (2016-2027)
Figure 20: Global Percentage share of Drugs marketed for AATD (2017)
Figure 21: Global Percentage share of Drugs marketed for AATD (2027)
Figure 22: Global Market Sales of Alpha Antitrypsin Deficiency by Therapies in USD, Million (2016-2027)
Figure 23: Global Treated Population of Alpha Antitrypsin Deficiency (2016-2027)
Figure 24: United States Market Size of Alpha Antitrypsin Deficiency in USD, Million (2016-2027)
Figure 25: Percentage share of Drugs marketed for AATD in United States (2017)
Figure 26: Percentage share of Drugs marketed for AATD in United States (2027)
Figure 27: US Market Sales of Alpha Antitrypsin Deficiency by Products in USD, Million (2016-2027)
Figure 28: Treated Population of Alpha Antitrypsin Deficiency in the United States (2016-2027)
Figure 29: Germany Market Size of Alpha Antitrypsin Deficiency in USD, Million (2016-2027)
Figure 30: Percentage share of Drugs marketed for AATD in Germany (2017)
Figure 31: Percentage share of Drugs marketed for AATD in Germany (2027)
Figure 32: Germany Market Sales of Alpha Antitrypsin Deficiency by Products in USD, Million (2016-2027)
Figure 33: Treated Population of Alpha Antitrypsin Deficiency in the Germany (2016-2027)
Figure 34: France Market Size of Alpha Antitrypsin Deficiency in USD, Million (2016-2027)
Figure 35: Percentage share of Drugs marketed for AATD in France (2017)
Figure 36: Percentage share of Drugs marketed for AATD in France (2027)
Figure 37: France Market Sales of Alpha Antitrypsin Deficiency by Products in USD, Million (2016-2027)
Figure 38: Treated Population of Alpha Antitrypsin Deficiency in the France (2016-2027)
Figure 39: Italy Market Size of Alpha Antitrypsin Deficiency in USD, Million (2016-2027)
Figure 40: Percentage share of Drugs marketed for AATD in Italy (2017)
Figure 41: Percentage share of Drugs marketed for AATD in Italy (2027)
Figure 42: Italy Market Sales of Alpha Antitrypsin Deficiency by Products in USD, Million (2016-2027)
Figure 43: Treated Population of Alpha Antitrypsin Deficiency in the Italy( 2016-2027)
Figure 44: Spain Market Size of Alpha Antitrypsin Deficiency in USD, Million (2016-2027)
Figure 45: Percentage share of Drugs marketed for AATD in Spain (2017)
Figure 46: Percentage share of Drugs marketed for AATD in Spain (2027)
Figure 47: Spain Market Sales of Alpha Antitrypsin Deficiency by Products in USD, Million (2016-2027)
Figure 48: Treated Population of Alpha Antitrypsin Deficiency in the Spain (2016-2027)
Figure 49: United Kingdom Market Size of Alpha Antitrypsin Deficiency in USD, Million (2016-2027)
Figure 50: Percentage share of Drugs marketed for AATD in UK (2018)
Figure 51: Percentage share of Drugs marketed for AATD in UK (2027)
Figure 52: United Kingdom Market Sales of Alpha Antitrypsin Deficiency by Products in USD, Million (2016-2027)
Figure 53: Treated Population of Alpha Antitrypsin Deficiency in the UK (2016-2027)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll